Galmed Pharmaceuticals (GLMD) Short Interest Ratio & Short Volume → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free GLMD Stock Alerts $0.36 0.00 (0.00%) (As of 04/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Galmed Pharmaceuticals Short Interest DataCurrent Short Volume39,200 sharesPrevious Short Volume6,200 sharesChange Vs. Previous Month+532.26%Dollar Volume Sold Short$13,574.96Short Interest Ratio / Days to Cover0.2Last Record DateMarch 31, 2024Outstanding Shares5,050,000 sharesFloat Size3,570,000 sharesShort Percent of Float1.10%Today's Trading Volume46,339 sharesAverage Trading Volume267,530 sharesToday's Volume Vs. Average17% Short Selling Galmed Pharmaceuticals ? Sign up to receive the latest short interest report for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatGLMD Short Interest Over TimeGLMD Days to Cover Over TimeGLMD Percentage of Float Shorted Over Time Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! Galmed Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202439,200 shares $13,574.96 +532.3%1.1%0.2 $0.35 3/15/20246,200 shares $1,891.62 -84.9%0.2%0 $0.31 2/29/202441,000 shares $16,322.10 -46.1%1.2%0.4 $0.40 2/15/202476,000 shares $28,887.60 +560.9%2.1%0.6 $0.38 1/31/202411,500 shares $4,311.35 -79.1%0.3%0.1 $0.37 1/15/202455,100 shares $25,015.40 -9.7%1.5%0.3 $0.45 Get the Latest News and Ratings for GLMD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 12/31/202361,000 shares $27,755.00 +65.3%1.7%0.4 $0.46 12/15/202336,900 shares $13,165.92 -56.9%1.0%0.2 $0.36 11/30/202385,700 shares $30,423.50 +564.3%2.4%0.4 $0.36 11/15/202312,900 shares $5,160.00 +17.3%0.4%0.1 $0.40 10/31/202311,000 shares $4,180.00 -1.8%0.3%0.2 $0.38 10/15/202311,200 shares $4,592.00 +75.0%0.3%0.1 $0.41 9/30/20236,400 shares $3,968.00 +88.2%0.2%0 $0.62 9/15/20233,400 shares $2,515.66 -52.8%0.1%0 $0.74 8/31/20237,200 shares $5,824.80 -32.7%0.2%0 $0.81 8/15/202310,700 shares $8,669.14 -61.1%0.3%0 $0.81 7/31/202327,500 shares $31,625.00 -92.3%1.5%0.1 $1.15 7/15/2023357,100 shares $517,795.00 +2,668.2%20.1%1.3 $1.45 6/30/202312,900 shares $37,539.00 -6.5%0.9%0.1 $2.91 6/15/202313,800 shares $51,474.00 -14.3%1.0%0.5 $3.73 5/31/202316,100 shares $74,221.00 -18.7%1.1%0.7 $4.61 5/15/202319,800 shares $0.00 +1,700.0%1.4%0.9 $0.00 4/30/202317,200 shares $5,332.00 -6.5%0.1%0.1 $0.31 4/15/202318,400 shares $5,704.00 -30.3%0.1%0.3 $0.31 3/31/202326,400 shares $11,259.60 -28.5%0.1%0.3 $0.43 3/15/202336,900 shares $17,239.68 +58.4%0.2%0.3 $0.47 2/28/202323,300 shares $11,184.00 -32.1%0.1%0.2 $0.48 2/15/202334,300 shares $20,923.00 +106.6%0.2%0.2 $0.61 1/31/202316,600 shares $10,974.26 -88.4%0.1%0.1 $0.66 1/15/2023143,500 shares $115,058.30 -2.3%0.7%1.1 $0.80 12/30/2022146,900 shares $73,450.00 +57.3%0.7%1.3 $0.50 12/15/202293,400 shares $27,086.00 +233.6%0.4%1.1 $0.29 11/30/202228,000 shares $8,173.20 +53.0%0.1%0.8 $0.29 11/15/202218,300 shares $6,101.22 -45.9%0.1%0.4 $0.33 10/31/202233,800 shares $12,847.38 +80.8%0.2%0.6 $0.38 10/15/202218,700 shares $7,264.95 +22.2%0.1%0.3 $0.39 9/30/202215,300 shares $4,759.59 -57.5%0.1%0.2 $0.31 9/15/202236,000 shares $16,563.60 -35.5%0.2%0.4 $0.46 8/31/202255,800 shares $25,896.78 +234.1%0.3%0.5 $0.46 8/15/202216,700 shares $7,424.82 -34.0%0.1%0.2 $0.44The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! GLMD Short Interest - Frequently Asked Questions What is Galmed Pharmaceuticals' current short interest? Short interest is the volume of Galmed Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 39,200 shares of GLMD short. 1.10% of Galmed Pharmaceuticals' shares are currently sold short. Learn More on Galmed Pharmaceuticals' current short interest. Which institutional investors are shorting Galmed Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Galmed Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Galmed Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.10% of Galmed Pharmaceuticals' floating shares are currently sold short. Is Galmed Pharmaceuticals' short interest increasing or decreasing? Galmed Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 39,200 shares, an increase of 532.3% from the previous total of 6,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Galmed Pharmaceuticals' float size? Galmed Pharmaceuticals currently has issued a total of 5,050,000 shares. Some of Galmed Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Galmed Pharmaceuticals currently has a public float of 3,570,000 shares. How does Galmed Pharmaceuticals' short interest compare to its competitors? 1.10% of Galmed Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Galmed Pharmaceuticals: Panbela Therapeutics, Inc. (2.36%), Dermata Therapeutics, Inc. (1.73%), GRI Bio, Inc. (1.81%), Comera Life Sciences Holdings, Inc. (2.38%), InMed Pharmaceuticals Inc. (0.17%), Qualigen Therapeutics, Inc. (1.74%), Lucy Scientific Discovery Inc. (2.95%), NeuBase Therapeutics, Inc. (4.92%), Bio-Path Holdings, Inc. (8.97%), Clearmind Medicine Inc. (6.12%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Galmed Pharmaceuticals stock? Short selling GLMD is an investing strategy that aims to generate trading profit from Galmed Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Galmed Pharmaceuticals? A short squeeze for Galmed Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GLMD, which in turn drives the price of the stock up even further. How often is Galmed Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GLMD, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Panbela Therapeutics Short Interest Data Dermata Therapeutics Short Interest Data GRI Bio Short Interest Data Comera Life Sciences Short Interest Data InMed Pharmaceuticals Short Interest Data Qualigen Therapeutics Short Interest Data Lucy Scientific Discovery Short Interest Data NeuBase Therapeutics Short Interest Data Bio-Path Short Interest Data Clearmind Medicine Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GLMD) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profits[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe “Perfect Storm” for GoldGold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressYour Money is Not SafeAmerican AlternativeUrgent alert: open this for a huge profit potentialTimothy Sykes